Mannheim (Germany), September 2025 – At this year’s CPHI Europe in Frankfurt (28–30 October), BENEO will showcase the latest advancements in granulation with its pharmaceutical-grade isomalt excipient: galenIQ™. Visitors are invited to connect with the BENEO team at Stand 8.0L70, where experts will present new data, application samples, and formulation insights for oral dosage forms.
As continuous manufacturing becomes increasingly prominent in the pharmaceutical industry, BENEO’s galenIQ™ offers a compelling binder solution. Its unique performance profile includes fast preparation, robust granule formation, excellent flowability, and rapid dissolution – key factors for success in both twin screw and high-shear granulation.
Designed to meet the dual requirements of efficient manufacturing and enhanced patient compliance, galenIQ™ combines technical performance with sensory appeal. Thanks to its pleasant, sweet taste and plant-based origin, it supports the development of more palatable and patient-friendly dosage forms. Produced from beet sugar, BENEO’s filler-binder is non-synthetic and peroxide-free. In addition to aligning with modern consumer needs, it also provides formulators with a stable, consistent, and reliable excipient solution.
Proven performance in modern granulation
In recent internal trials, galenIQ™ delivered impressive results across key metrics for twin screw granulation (TSG). It showed excellent compactability and produced high-strength tablets (>1.8 MPa) while maintaining rapid disintegration – a desired combination in continuous manufacturing. These attributes make galenIQ™ a particularly strong performer for TSG lines when stability, throughput, and formulation flexibility are essential.
“galenIQ™ sets a new benchmark in excipient functionality. Unlike traditional binders, the isomalt-based excipient showed lower sensitivity to concentration levels. Formulators benefit from greater process control and more consistent product quality. This combination of reliability and performance makes galenIQ™ a strong choice for manufacturers seeking both efficiency in production and confidence in regulatory compliance,” says Dr Maj-Britt Cepok, Head of Pharma at BENEO.
Discover galenIQ™ at Stand 8.0L70
Meet the BENEO team during the show and discover why galenIQ™ is the granulation binder of choice for modern manufacturing. Experience new data, application samples, and expert insights that show how this excipient performs in granulation processes – all while enhancing patient compliance. Don’t miss the chance to see how galenIQ™ can elevate your formulations and streamline your processes.
Meet BENEO at CPHI Europe 2025
📍 Stand 8.0L70 | Messe Frankfurt
📅 28–30 October 2025
More information about BENEO and its portfolio can be found at www.beneo.com/news or on LinkedIn.
